Skip to content
Open access

Heterogeneity in plasma p‐tau217 response and its association with cognitive trajectories under lecanemab treatment

Jul 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 28 references
Medicine

Abstract

Plasma phosphorylated tau 217 (p‐tau217) is a promising biomarker for monitoring treatment response in Alzheimer's disease (AD), but its longitudinal dynamics and clinical relevance remain unclear.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.